OKAVA Announces Publication of a Proof-of-Concept Validation Study for OKV-119, Its Pioneering Long-Term Drug Delivery System
Published in Frontiers in Veterinary Research, the Feasibility of Long-Term Drug Delivery of the GLP-1 Exenatide is Demonstrated in this Study Conducted in Cats
OKAVA Announces Publication of Proof-of-Concept Validation Studyfor OKV-1001, Its Pioneering Modified Release Mycophenolate Product for Immune-Mediated Diseases
Published in Frontiers in Veterinary Research, This Proof-of-Concept Study Demonstrates the Clinical Advantages of OKV-1001 Over Immediate-Release CellCept®
OKAVA Awarded $500,000 Grant by the FDA for Clinical Trial of OKV-1001 for the Treatment Blood Disorder
The Competitive Grant Awarded to OKAVA Demonstrates That the FDA Considers
OKV-1001 To Be an Innovative Product That Addresses High Unmet Medical Need
OKAVA Announces Receipt of MUMS Drug Designation in Dogs for OKV-1001
MUMS Designation Places OKV-1001 on an Accelerated Conditional Approval
Pathway and Demonstrates That the FDA Considers OKV-1001 To Be an Innovative
Product That Addresses High Unmet Medical Need
OKVA Announces Collaboration with Nano Precision Medical, Inc. on Long-Term Drug Delivery System to Develop Novel Therapeutics for Animal Health
Collaboration Leverages NanoPortal™, A Best-in-Class Drug-Device Technology Developed by Nano Precision Medical, For Use in Feline Obesity and Diabetes
OKAVA Announces Positive FDA Pre-Submission Conference For OKV-1001 To Treat A Deadly Blood Disorder In Dogs
A Clear Path to Regulatory Approval Has Been Established For the Use Of OKV-
1001 in IMHA